Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01928186
Other study ID # 7536
Secondary ID NCI-2013-0138075
Status Completed
Phase N/A
First received
Last updated
Start date September 2011
Est. completion date July 20, 2015

Study information

Verified date April 2018
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage I-III breast cancer. Comparing results of diagnostic procedures done before and during hormone therapy may help doctors predict a patient's response to treatment and help plan the best treatment.


Description:

PRIMARY OBJECTIVES:

I. Measure the effect of a short course of endocrine therapy on primary breast cancer metabolism and proliferation by measuring changes in serial FLT PET measures pre and post a short course of endocrine therapy.

SECONDARY OBJECTIVES:

I. Compare changes in imaging measures to tissue measures of response, in particular antigen identified by proliferation-related Ki-67 antigen (Ki-67), in the pre-therapy biopsy versus the post-therapy surgical specimen.

II. Correlate imaging measures to measures of gene expression from pre and post therapy assays to determine if there are molecular changes associated with early response to therapy.

OUTLINE:

Patients undergo FLT PET at baseline and 1-6 weeks after the start of treatment.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date July 20, 2015
Est. primary completion date July 20, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- A new diagnosis of invasive breast cancer > 1.0 cm in size, ER+ clinical stage I-III

- Patient must have surgical resection followed by systemic adjuvant therapy with an aromatase inhibitor (AIs) as part of planned treatment; any approved AI at standard clinical dosing may be used; in pre-menopausal patients, ovarian suppression with a gonadotropin-releasing hormone (GnRH) agonist will be started prior to initiation of the AI on a separate clinical trial in parallel with the imaging study

- Have tissue block available from core biopsy for correlative biomarkers and genomic assay

- Have menopausal status determined prior to study enrollment; for study purposes, postmenopausal is defined as

- A prior documented bilateral oophorectomy, or

- A history of at least 12 months without spontaneous menstrual bleeding, or

- Age 60 or older with a prior hysterectomy without oophorectomy, or

- Age less than 60 with a prior hysterectomy without oophorectomy (or in whom the status of the ovaries is unknown) with a documented follicle-stimulating hormone (FSH) level demonstrating confirmatory elevation in the postmenopausal range for the lab

- Negative pregnancy test within 7 days of baseline positron emission tomography (PET) scan for pre-menopausal patients

- Tumor HER2/neu expression must be determined (as part of standard clinical care) prior to study enrollment; HER2 may be tested by any Food and Drug Administration (FDA) approved HER2 testing method; if determination is intermediate by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) or another alternate HER2 test must be performed

- Be a candidate for [18F]FLT PET imaging

- Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific screening procedures

- Be willing and able to comply with scheduled visits and other trial procedures

Exclusion Criteria:

- Current use of aromatase inhibitor as prevention or treatment for breast cancer

- Life expectancy of less than two months

- HER2/neu positive by IHC and/or another FDA approved HER2 testing method

- Inability to tolerate scanning (e.g. - claustrophobia, severe pain)

- Weight exceeding capacity of imaging table

Study Design


Intervention

Drug:
Fluorothymidine F-18
Undergo FLT PET
Procedure:
Positron Emission Tomography
Undergo FLT PET
Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Run-in (short pre-surgery course) of endocrine-targeted therapy
Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.

Locations

Country Name City State
United States Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Washington National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Post-treatment Gene Expression Levels Analyzed using BeadStudio software. Four clustering metrics for calculating dissimilarities (correlation, absolute correlation, Euclidean, and Manhattan) are available in BeadStudio and will be applied using standard analysis methods and diagnostics in BioConductor. To focus the analysis, proposed gene sets will be examined based on biological pathways and molecular signatures. 1 to 6 weeks post-therapy start
Other Pre-treatment Gene Expression Levels Analyzed using BeadStudio software. Four clustering metrics for calculating dissimilarities (correlation, absolute correlation, Euclidean, and Manhattan) are available in BeadStudio and will be applied using standard analysis methods and diagnostics in BioConductor. To focus the analysis, proposed gene sets will be examined based on biological pathways and molecular signatures. Baseline
Primary Percent Change in Net Influx Constant (Ki) by FLT PET Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed.
Association between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response.
Baseline to up to 6 weeks
Primary Percent Change in SUV by FLT PET Percent change between pre-treatment (baseline) and post-therapy measurements of FLT standardized uptake value (SUV) in breast tumors will be computed. Baseline to up to 6 weeks
Primary Percentage of Ki-67 Positive Tumor Cells in Surgical (Post-therapy) Sample Surgically removed breast tumor tissue is stained using immuno-histochemistry techniques to visualize dividing cells expressing the Ki-67 protein, which is a cellular marker for proliferation. 1 to 6 weeks post-therapy start
Primary Percentage Change in Ki-67 Positive Cells Between Pre-therapy and Post-therapy Tumor Specimens Tumor tissue samples from pre-treatment (baseline) biopsy and post-treatment surgery are stained using immuno-histochemistry techniques to visualize dividing cells expressing the Ki-67 protein, which is a cellular marker for proliferation.
The % values of positive cells from the baseline and post-treatment samples are then compared for each individual patient.
Association between Ki-67 and KFLT decline will be analyzed to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response.
Baseline to up to 6 weeks
Secondary Percentage Change in K1 (Blood Flow Parameter) by FLT PET Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed. Baseline to up to 6 weeks
Secondary Baseline Ki (Flux Constant) Values by FLT PET Ki (flux constant) in breast tumor tissue as determined by the pre-therapy (baseline) FLT PET scan Baseline
Secondary Baseline FLT Transport (K1) Values by FLT PET K1 (blood flow measure) in breast tumor tissue as determined by the pre-therapy (baseline) FLT PET Baseline
Secondary Baseline Standardized Uptake Values (SUV) by FLT PET FLT SUV in breast tumor tissue as determined by the pre-therapy (baseline) FLT PET Baseline
Secondary Post-therapy Ki (Flux Constant) Values by FLT PET Ki (flux constant) in breast tumor tissue as determined by the post-therapy FLT PET 1 to 6 weeks post-therapy start
Secondary Post-treatment FLT Transport (K1) Values by FLT PET K1 (blood flow measure) in breast tumor tissue as determined by the post-therapy FLT PET 1 to 6 weeks post-therapy start
Secondary Post-treatment Standardized Uptake Values (SUV) by FLT PET FLT SUV in breast tumor tissue as determined by the post-treatment FLT PET 1 to 6 weeks post-therapy start
See also
  Status Clinical Trial Phase
Completed NCT02235051 - Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors N/A
Terminated NCT02454777 - High-Intensity Interval Training for Stage I-III Breast Cancer Patients N/A
Completed NCT03061175 - Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy N/A
Completed NCT01959490 - Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer Phase 2
Recruiting NCT03156309 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Terminated NCT01368263 - Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer Phase 2
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Completed NCT00425672 - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment Phase 1/Phase 2
Completed NCT00070252 - Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT02780401 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT01478477 - Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole N/A
Completed NCT03364348 - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Phase 1
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Withdrawn NCT01695057 - Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer N/A
Completed NCT01672684 - Phase I: At-Home Support for Rural Women Using Group Video Calling Phase 1
Terminated NCT01234532 - Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00416715 - Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer Phase 2
Completed NCT00119262 - Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer Phase 2